Chardan Capital Markets Starts Novavax (NVAX) at Neutral
Tweet
Share
E-mailGet Alerts NVAX Hot Sheet
Price: $9.26 +2.32%
Rating Summary:
10 Buy, 3 Hold, 5 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 5 | New: 3
Rating Summary:
10 Buy, 3 Hold, 5 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 5 | New: 3
Join SI Premium – FREE
Chardan Capital Markets initiated coverage on Novavax (NASDAQ: NVAX) with a Neutral rating and a price target of $5.75.
For an analyst ratings summary and ratings history on Novavax click here. For more ratings news on Novavax click here.
Shares of Novavax closed at $5.49 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Novavax's Nuvaxovid wins approval in U.S., EU, Japan for 2026-2027
- BioLineRx plans $3.75M share offering at $2.78 per ADS
- Hyperliquid Strategies, Inc. (PURR) PT Raised to $17 at Chardan
Create E-mail Alert Related Categories
New CoverageRelated Entities
Chardan Capital MarketsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
